Article

Therapeutic vulnerability to PARP1/2 inhibition in <i>RB1</i> -mutant osteosarcoma

2020-12-28

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Loss-of-function mutations of the retinoblastoma tumour suppressor RB1 are key drivers in cancer, with prominent involvement in the natural history of Osteosarcoma (OS). RB1 loss-of-function compromises genome maintenance in cells and hence could yield vulnerability to therapeutics targeting such processes. <h4>Method</h4> We assessed the response to Poly-ADP-Polymerase1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 858be191-6243-5653-9ced-1ff79f468b7d
DOI: 10.1101/2020.12.28.424497

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic vulnerability to PARP1/2 inhibition in <i>RB1</i> -mutant osteosarcomaDOI 10.1101/2020.12.28.424497Read

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity Read

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.Semantic proximity Read

Characterization of a <i>RAD51C</i> -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance DevelopmentSemantic proximity Read

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian CancerSemantic proximity Read

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.Semantic proximity Read

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation responseSemantic proximity Read

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeuticsSemantic proximity Read

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor MicroenvironmentSemantic proximity Read

Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinomaSemantic proximity Read

Defective homologous recombination DNA repair as therapeutic target in advanced chordomaSemantic proximity Read

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1 -Deficient CellsSemantic proximity Read